Aspen’s profit after tax increases by 35% Johannesburg – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a leading pharmaceutical manufacturer in the southern hemisphere, has announced pleasing results for the six months ended 31 December 2015. The Group delivered solid growth in a period marked by economic stress and weakening market currencies. The factors set out below have significantly affected the comparability of the results with those of the prior period: The completion on 31 August 2015 of the divestment of the generics business conducted in Australia as well as certain branded products distributed in Australia to Strides group companies, the related termination of license arrangements in Australia and the completion on 1 October 2015 of the divestment of a portfolio of products distributed in South Africa to Litha Pharma (collectively “the Divestments”). The Divestments gave rise to a pre-tax profit on disposal of R1.7 billion. However, as a consequence of the timing of these transactions, the contribution to the trading results by the Divestments is substantially reduced in the current period. In the period from 1 July 2015 until the effective date of divestment, revenue from the Divestments was R202 million whereas revenue from the Divestments for the six months ended 31 December 2014 was R1 148 million. The economic situation in Venezuela deteriorated over the 6 months to December 2015 and the Venezuelan authorities have increasingly limited authorisations to pay for pharmaceutical imports using the official CENCOEX rate during this period of Venezuelan Bolivars (“VEF”) 6.30 per US Dollar (“USD”). As a consequence of the limited payment approvals and the uncertain economic and political situation in Venezuela, the Group has concluded that it would be more appropriate to apply the SIMADI exchange rate of VEF 200 per USD to report the Venezuelan business’ financial position, results of its operations and cash flows for the 6 months ended 31 December 2015. This has resulted in a one-off currency devaluation loss on foreign denominated liabilities of R841million. The profit arising from the Divestments, the currency devaluation loss and the hyperinflationary adjustments relating to Venezuela are excluded in determining normalised headline earnings per share (“NHEPS”) which increased by 14%. In order to provide meaningful comparability of the financial performance of the ongoing underlying business, a measure described as comparable NHEPS has been determined by removing the contribution by the Divestments from NHEPS and including the results of Aspen’s business in Venezuela translated at VEF 200 per USD in the prior reporting period. Comparable NHEPS for the 6 months ended 31 December 2015 was 640,9 cents, an increase of 21%. Applying the same principles, comparable revenue increased by 8% and comparable operating profit increased by 8%. GROUP PERFORMANCE Revenue excluding the effect of the Divestments, increased by 8% to R 17.3 billion. Profit after tax increased 35% to R3.3 billion. Comparable normalised headline earnings per share increased by 21% to 640,9 cents. Normalised headline earnings per share improved by 14% to 655.5 cents. Borrowings, net of cash, increased R3.5 billion over the period to R33.5 billion. Group operating cash flows were negatively affected by a R1.8 billion increase in working capital over the period. Stephen Saad, Aspen Group Chief Executive said, “Performance was led by the International business where the Europe CIS region made a strong contribution. The nutritional products in South Africa and in Asia Pacific also achieved good growth. The completion of the Divestments marks an important step in achieving increased focus in the South African and Asia Pacific businesses. Further meaningful advances in the implementation of Aspen’s strategic objectives have been made and we are seeking to grow the business in targeted therapeutic categories. We remain alert to opportunities to expand our product portfolio in these areas of focus.” INTERNATIONAL BUSINESS The International Business improved revenue 2% to R9.0 billion and raised operating profit before amortisation, adjusted for specific non-trading items (“EBITA”), 16% to R2.8 billion. Revenue was unfavourably affected by R836 million due to the devaluation of the Venezuelan contribution. Excluding the effect of the devaluation, revenue increased 14% in the remainder of the International business. Revenue from customers in Europe and the Commonwealth of Independent States (“Europe CIS”) increased 21% to R6.1 billion. Finished dose form pharmaceutical sales to healthcare providers were up 20% to R4.1 billion. The acquisition of Mono-Embolex, with almost all of its sales in Germany, in the second half of the previous year further strengthened Aspen’s offering in this therapeutic area and added to growth. However, the contribution from Russia fell sharply due to the significant weakening of the Ruble. API sales continued to grow and were the largest part of the balance of the revenue from Europe CIS. Sales to customers in Latin America (excluding Venezuela) declined by 1% to R1.7 billion, unfavourably influenced by difficult socio-economic conditions in Brazil. The nutritionals products in the region maintained their positive growth momentum with revenue rising 12%. Demand for Aspen’s pharmaceutical products was strong, but performance has continued to be suppressed by unreliable supply of certain key products by contract manufacturers. The devalued contribution from Venezuela is no longer material to the Group.| Sales to customers in the Rest of the World increased 4% to R922 million, led by a positive performance in the Middle East North Africa territory. The installation of a new high-speed pre-filled syringe filling line at Aspen Notre Dame de Bondeville (“Aspen NDB”) was completed during the period and commercial production is about to commence. At Aspen Oss capital expenditure projects are ongoing, focused on the sustainability of the site. SOUTH AFRICAN BUSINESS In the South African business revenue was 3% lower at R4.2 billion. Excluding the effect of the Divestments, revenue improved by 4%. The nutritionals products were the leading performer, with revenue growing 15% to R402 million. In the balance of the private sector, branded and generic pharmaceuticals performed satisfactorily. However, supply problems severely undermined the performance of the over-the-counter (“OTC”) products with a consequential decline in key OTC brands. Sales in the public sector (excluding… Continue reading Aspen’s profit after tax increases by 35%
